Ophthalmology Drug And Device Market Size (2024 - 2029)

The ophthalmology drug and device market is projected to experience growth over the forecast period, driven by factors such as the increasing prevalence of eye diseases, demographic shifts, and technological advancements in ophthalmology. The market's expansion is supported by the rising geriatric population and the demand for cataract surgeries, which are crucial for improving the quality of life. Despite the initial impact of the COVID-19 pandemic, the market has recovered and is expected to continue its upward trajectory due to new product launches and strategic initiatives by key players. However, challenges such as the high cost of ophthalmic devices and stringent FDA regulations may hinder market growth.

Market Size of Ophthalmology Drug And Device Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Ophthalmology Drug and Device Market
Study Period 2019 - 2029
Market Size (2024) USD 38.07 Billion
Market Size (2029) USD 47.13 Billion
CAGR (2024 - 2029) 4.36 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Ophthalmology Drug and Device Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Ophthalmology Drug & Device Market Analysis

The Ophthalmology Drug And Device Market size is estimated at USD 38.07 billion in 2024, and is expected to reach USD 47.13 billion by 2029, growing at a CAGR of 4.36% during the forecast period (2024-2029).

The COVID-19 pandemic had a significant impact on the market initially as several countries were in lockdown, and trades were suspended with other countries with travel restrictions, leading to a decline in eye diagnoses. As a cautionary measure, many ophthalmologists temporarily closed their practices during the pandemic. According to an article published by the Indian Journal of Ophthalmology in December 2021, a survey was conducted among the All India Ophthalmological Society (AIOS) members, which stated that COVID-19 had adversely affected ophthalmic care services across the whole of India. As the number of COVID-19 cases has decreased significantly, the market has recovered and started to gain traction. Hence, the market is expected to have stable growth during the forecast period of the study.

Certain factors driving the market's growth include the impact of the prevalence of eye disease, demographic shift, technological advancements in the field of ophthalmology, and the rising geriatric population. According to the data updated by WHO in October 2022, it is estimated at least 2.2 billion people will have a near or distant vision impairment globally. Among these, at least 1 billion people's vision impairment could have been prevented or yet to get addressed. These 1 billion people include those with moderate or severe distance vision impairment or blindness due to various diseases like unaddressed refractive error (88.4 million), cataract (94 million), age-related macular degeneration (8 million), glaucoma (7.7 million), diabetic retinopathy (3.9 million), as well as near vision impairment caused by unaddressed presbyopia (826 million). In many countries, cataract surgery is the most common surgical procedure performed, significantly improving the quality of life of the elderly population at low costs. An increase in the elderly population and the high prevalence of ophthalmic disorders increases the demand for ophthalmological devices and projects the future cataract surgery needs vital for human health resources, hospitals, and surgical centre management and planning. Other factors, such as the availability of new devices and new drugs and the growing incidence of eye disease, are also expected to drive the market over the forecast period.

In addition, new product launches and strategic activities by major players in the market are positively affecting the growth of the studied market. For example, in June 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. launched ranibizumab-nuna (Byooviz, Biogen), an ophthalmic biosimilar referencing ranibizumab (Lucentis, Genentech) in the US. Thus, due to the product launches and partnerships, the studied market is expected to grow significantly over the forecast period.

Therefore, owing to the factors above, the studied market is anticipated to witness growth over the analysis period. However, the higher cost of ophthalmic devices and treatment and strict FDA guidelines for drug approval is likely to impede the market's growth.

Ophthalmology Drug & Device Industry Segmentation

As per the scope of the report, ophthalmology drug and device includes all the products that ophthalmologists use to diagnose, treat, and care for the eyes. The Ophthalmology Drug and Device Market are segmented by product (devices and drugs), disease (Glaucoma, Cataract, age-related macular degeneration, inflammatory diseases, refractive disorders, and other diseases), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value in ( USD million) for the abovementioned segments.

By Product
Devices
Surgical Devices
Intraocular Lenses
Ophthalmic Lasers
Other Surgical Devices
Diagnostic Devices
Drugs
Glaucoma Drugs
Retinal Disorder Drugs
Dry Eye Drugs
Allergic Conjunctivitis and Inflammation Drugs
Other Drugs
By Disease
Glaucoma
Cataract
Age-Related Macular Degeneration
Inflammatory Diseases
Refractive Disorders
Other Diseases
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Ophthalmology Drug And Device Market Size Summary

The ophthalmology drug and device market is poised for steady growth over the forecast period, driven by several key factors. The market's recovery from the initial impacts of the COVID-19 pandemic has been bolstered by the increasing prevalence of eye diseases, demographic shifts, and technological advancements in ophthalmology. The rising geriatric population, coupled with the high incidence of conditions such as glaucoma, cataracts, and diabetic retinopathy, is expected to significantly boost the demand for ophthalmological devices and treatments. The market is further supported by new product launches and strategic partnerships among major industry players, which are enhancing the availability and efficacy of ophthalmic solutions. Despite challenges such as the high cost of devices and stringent regulatory requirements, the market is anticipated to experience robust growth.

Regionally, North America is expected to witness significant expansion due to its well-established healthcare infrastructure and the increasing elderly population. The United States, in particular, is seeing a rise in eye disorders, which is driving demand for ophthalmic drugs and devices. The presence of major market players and continuous product innovations are contributing to the region's growth. Globally, the market is moderately fragmented, with key players like Alcon Inc., Bausch Health Companies Inc., and Johnson & Johnson leading the charge. These companies are actively involved in launching new products and expanding their market presence, which is expected to further propel the market's growth trajectory.

Explore More

Ophthalmology Drug And Device Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Demographic Shift and Impact of Prevalence of Eye Disease

      2. 1.2.2 Technological Advancements in the Field of Ophthalmology

    3. 1.3 Market Restraints

      1. 1.3.1 Higher Cost of the Ophthalmic Devices and Treatment

      2. 1.3.2 Strict FDA Guidelines for Drug Approval

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Product

      1. 2.1.1 Devices

        1. 2.1.1.1 Surgical Devices

          1. 2.1.1.1.1 Intraocular Lenses

          2. 2.1.1.1.2 Ophthalmic Lasers

          3. 2.1.1.1.3 Other Surgical Devices

        2. 2.1.1.2 Diagnostic Devices

      2. 2.1.2 Drugs

        1. 2.1.2.1 Glaucoma Drugs

        2. 2.1.2.2 Retinal Disorder Drugs

        3. 2.1.2.3 Dry Eye Drugs

        4. 2.1.2.4 Allergic Conjunctivitis and Inflammation Drugs

        5. 2.1.2.5 Other Drugs

    2. 2.2 By Disease

      1. 2.2.1 Glaucoma

      2. 2.2.2 Cataract

      3. 2.2.3 Age-Related Macular Degeneration

      4. 2.2.4 Inflammatory Diseases

      5. 2.2.5 Refractive Disorders

      6. 2.2.6 Other Diseases

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Ophthalmology Drug And Device Market Size FAQs

The Ophthalmology Drug And Device Market size is expected to reach USD 38.07 billion in 2024 and grow at a CAGR of 4.36% to reach USD 47.13 billion by 2029.

In 2024, the Ophthalmology Drug And Device Market size is expected to reach USD 38.07 billion.

Ophthalmology Drug and Device Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)